2024 | Wyatt AW, Litière S, Bidard FC, Cabel L, Dyrskjøt L, Karlovich CA, Pantel K, Petrie J, Philip R, Andrews HS, Vellanki PJ, Tolmeijer SH, Villalobos Alberu X, Alfano C, Bogaerts J, Calvo E, Chen AP, Toledo RA, de Vries EGE, Seymour L, Laurie SA, Garralda E. | Plasma ctDNA as a treatment response biomarker in metastatic cancers: evaluation by the RECIST working group | Clinical Cancer Research | | | |
2024 | Nakajima EC, Simpson A, Bogaerts J, de Vries EGE, Do R, Garalda E, Goldmacher G, Kinahan PE, Lambin P, LeStage B, Li Q, Lin F, Litière S, Perez-Lopez R, Petrick N, Schwartz L, Seymour L, Shankar L, Laurie SA | Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group. JCO Precis Oncol. | JCO Precision Oncology | 8 | Online only | Online only |
2019 | Litiere S, Isaac G, de Vries E, Bogaerts J, Chen A, Dancey J, Ford R, Gwyther S, Hoekstra O, Huang E, Lin N, Liu Y, Mandrekar S, Schwartz L, Shankar L, Therasse P, Seymour L. | RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis | Journal of Clinical Oncology | 37 | 13 | 1102-1110 |
2017 | Prof Lesley Seymour, Jan Bogaerts, PhD, Andrea Perrone, MD, Robert Ford, MD, Prof Lawrence H Schwartz, MD, Prof Sumithra Mandrekar, PhD, Nancy U Lin, MD, Saskia Litière, PhD, Prof Janet Dancey, MD, Alice Chen, MD, Prof F Stephen Hodi, MD, Patrick Therasse, MD, Prof Otto S Hoekstra, MD, Lalitha K Shankar, MD, Jedd D Wolchok, MD, Marcus Ballinger, PhD, Caroline Caramella, MD, Prof Elisabeth G E de Vries, MD on behalf of the RECIST working group | iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics | The Lancet Oncology | 18 | 3 | e143-e152 |
2017 | Saskia Litière, Sandra Collette, Elisabeth G. E. de Vries, Lesley Seymour & Jan Bogaerts | RECIST - learning from the past to build the future | Nature Reviews Clinical | 14 | 3 | 187-192 |
2016 | Lawrence H. Schwartz, Lesley Seymour, Saskia Litière, Robert Ford, Stephen Gwyther, Sumithra Mandrekar, Lalitha Shankar, Jan Bogaerts, Alice Chen, Janet Dancey, Wendy Hayes, F. Stephen Hodi, Otto S. Hoekstra, Erich P. Huang, Nancy Lin, Yan Liu, Patrick Therasse, Jedd D. Wolchok, Elisabeth de Vries | RECIST 1.1 - Standardisation and Disease Specific Adaptations: Perspectives from the RECIST Working Group | European Journal of Cancer | 62 | | 138-145 |
2016 | Lawrence H. Schwartz, Saskia Litière, Elisabeth de Vries, Robert Ford, Stephen Gwyther, Sumithra Mandrekar, Lalitha Shankar, Jan Bogaerts, Alice Chen, Janet Dancey, Wendy Hayes, F. Stephen Hodi, Otto S. Hoekstra, Erich P. Huang, Nancy Lin, Yan Liu, Patrick Therasse, Jedd D. Wolchok, Lesley Seymour | RECIST 1.1 - Update and Clarification: From the RECIST Committee | European Journal of Cancer | 62 | | 132-137 |
2015 | Ming-Wen An, Yu Han, Jeffrey P. Meyers, Jan Bogaerts, Daniel J. Sargent and Sumithra J. Mandrekar | Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods | Journal of Clinical Oncology | 33 | 34 | 4048-4057 |
2015 | Ming-Wen An, Xinxin Dong, Jeffrey Meyers, Yu Han, Axel Grothey, Jan Bogaerts, Daniel J. Sargent, Sumithra J. Mandrekar | Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival | Journal of the National Cancer Institute | 107 | 11 | |
2014 | Sumithra J. Mandrekar, Ming-Wen An, Jeffrey Meyers, Axel Grothey, Jan Bogaerts and Daniel J. Sargent | Evaluation of Alternate Categorical Tumor Metrics and Cut Points for Response Categorization Using the RECIST 1.1 Data Warehouse | Journal of Clinical Oncology | 32 | 8 | 841-850 |
2014 | Litiere S., De Vriese E.G.E., Seymour L., Sargent D., Shankar L., Bogaerts J. | Reply to Verlingue, Koscielny and Ferte | European Journal of Cancer | 50 | 16 | 2889-2891 |
2014 | Liu Y., Litiere S., De Vriese G., Sargent D., Shankar L., Bogaerts J., Seymour L. | The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: Results of a survey in the oncology community | European Journal of Cancer | 50 | 2 | 260-266 |
2014 | Mandrekar S.J., An M., Meyers J., Grothey A., Bogaerts J., Sargent D.J. | Evaluation of Alternate Categorical Tumor Metrics and Cut Points for Response Categorization Using the RECIST 1.1 Data Warehouse | Journal of Clinical Oncology | 32 | 8 | 841-852 |
2014 | Litiere S., De Vries E., Seymour L., Sargent D., Shankar L., Bogaerts J. | The components of progression as explanatory variables for overall survival in the Response Evaluation Criteria in Solid Tumours 1.1 database | European Journal of Cancer | 50 | | 1847-1853 |
2009 | Schwartz L.H., Bogaerts J., Ford R., Shankar L., Therasse P., Gwyther S., Eisenhauer E.A. | Evaluation of lymph nodes with RECIST 1.1 | European Journal of Cancer | 45 | 2 | 261-267 |
2009 | Ford R., Schwartz L., Dancey J., Dodd L.E., Eisenhauer E.A., Gwyther S., Rubinstein L., Sargent D., Shankar L., Therasse P., Verweij J. | Lessons learned from independent central review | European Journal of Cancer | 45 | 2 | 268-274 |
2009 | Ratain M.J., Sargent D. J. | Optimising the design of phase II oncology trials: The importance of randomisation | European Journal of Cancer | 45 | 2 | 275-280 |
2009 | | Editorial board | European Journal of Cancer | 45 | 2 | ii |
2009 | Sargent D.J., Rubinstein L., Schwartz L., Dancey J.E., Gatsonis C., Dodd L.E., Shankar L.K. | Validation of novel imaging methodologies for use as cancer clinical trial end-points | European Journal of Cancer | 45 | 2 | 290-299 |
2009 | Moskowitz C.S., Jia X., Schwartz L.H., Gönen M. | A simulation study to evaluate the impact of the number of lesions measured on response assessment | European Journal of Cancer | 45 | 2 | 300-310 |
2009 | Dancey J.E., Dodd L.E., Ford R., Kaplan R., Mooney M., Rubinstein L., Schwartz L.H., Shankar L., Therasse P. | Recommendations for the assessment of progression in randomised cancer treatment trials | European Journal of Cancer | 45 | 2 | 281-289 |
2009 | Verweij J., Therasse P., Eisenhauer E. | Cancer clinical trial outcomes: Any progress in tumour-size assessment? | European Journal of Cancer | 45 | 2 | 225-227 |
2009 | Bogaerts J., Ford R., Sargent D., Schwartz L.H., Rubinstein L., Lacombe D., Eisenhauer E., Verweij J., Therasse P. | Individual patient data analysis to assess modifications to the RECIST criteria | European Journal of Cancer | 45 | 2 | 248-260 |
2009 | Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M., Rubinstein L., Shankar L., Dodd L., Kaplan R., Lacombe D., Verweij J. | New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) | European Journal of Cancer | 45 | 2 | 228-247 |
2000 | Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., Verweij J., Van Glabbeke M., van Oosterom A.T., Christian M.C., Gwyther S.G. | New Guidelines to Evaluate the Response to Treatment in Solid Tumors | Journal of the National Cancer Institute | 92 | 3 | 205-216 |